scholarly article | Q13442814 |
P356 | DOI | 10.1007/S10067-013-2346-8 |
P698 | PubMed publication ID | 23912642 |
P50 | author | Suleyman Serdar Koca | Q88270656 |
Nevin Ilhan | Q41900799 | ||
P2093 | author name string | Ahmet Isik | |
Servet Yolbas | |||
Metin Ozgen | |||
Baris Gundogdu | |||
Fatma Akbas | |||
P2860 | cites work | Measuring disease activity and severity in scleroderma | Q70947293 |
Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies | Q72656941 | ||
A disease severity scale for systemic sclerosis: development and testing | Q73101147 | ||
The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials | Q74267099 | ||
Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice | Q77394043 | ||
Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae | Q80633633 | ||
Galectin-3 regulates myofibroblast activation and hepatic fibrosis | Q24546358 | ||
Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3 | Q24624887 | ||
Galectins. Structure and function of a large family of animal lectins | Q28246794 | ||
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. | Q32081724 | ||
Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast | Q34467951 | ||
Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis | Q34501897 | ||
Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. | Q34837887 | ||
The regulation of inflammation by galectin-3. | Q34991925 | ||
Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being | Q35169049 | ||
Assessment of disease activity. | Q35188039 | ||
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. | Q35550511 | ||
Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. | Q35809897 | ||
The current state of biomarkers in systemic sclerosis | Q35896754 | ||
Role of galectin-3 in acetaminophen-induced hepatotoxicity and inflammatory mediator production | Q35969291 | ||
Update on indices of disease activity in systemic sclerosis | Q36760739 | ||
The immunological potential of galectin-1 and -3. | Q37343666 | ||
Overview of pathogenesis of systemic sclerosis | Q37504301 | ||
Biomarkers in systemic sclerosis | Q37730018 | ||
Biomarkers for skin involvement and fibrotic activity in scleroderma | Q37912251 | ||
Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts | Q37956146 | ||
Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis | Q38497448 | ||
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee | Q39513167 | ||
Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis | Q40016270 | ||
Role of galectin-3 in human pulmonary fibrosis | Q40177839 | ||
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
Galectin 3 and its binding protein in rheumatoid arthritis. | Q42451393 | ||
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity. | Q53557883 | ||
Preliminary criteria for the classification of systemic sclerosis (scleroderma) | Q54165663 | ||
Scleroderma | Q54165664 | ||
Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis | Q61187743 | ||
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis | Q68330753 | ||
P433 | issue | 2 | |
P304 | page(s) | 215-220 | |
P577 | publication date | 2013-08-03 | |
P1433 | published in | Clinical Rheumatology | Q15754927 |
P1476 | title | Serum galectin-3 level in systemic sclerosis | |
P478 | volume | 33 |
Q47135290 | Association of Serum Galectin-3 with the Acute Exacerbation of Chronic Obstructive Pulmonary Disease. |
Q90639151 | Early Hyperbaric Oxygen Treatment Attenuates Burn-Induced Neuroinflammation by Inhibiting the Galectin-3-Dependent Toll-Like Receptor-4 Pathway in a Rat Model |
Q92312918 | Galectin 3: an extraordinary multifunctional protein in dermatology. Current knowledge and perspectives |
Q90073141 | Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases |
Q57274173 | Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers |
Q38542678 | Galectin-3 in autoimmunity and autoimmune diseases |
Q90640127 | Galectin-3 orchestrates the histology of mesentery and protects liver during lupus-like syndrome induced by pristane |
Q48159180 | Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. |
Q39201281 | High Expression of Galectin-3 in Patients with IgG4-Related Disease: A Proteomic Approach |
Q37339791 | Prognostic value of plasma galectin-3 levels after aneurysmal subarachnoid hemorrhage |
Q41449179 | Serum galectin-3 levels and delirium among postpartum intensive care unit women. |
Q50068427 | The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients |
Q36601648 | Vesicular Galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles |
Search more.